Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Seedance 2.0 can take camera movement, visual effects, and motion into account. Seedance 2.0 can take camera movement, visual effects, and motion into account. is a news writer who covers the ...

Dina Zipin has 10+ years of experience as a writer and editor and 2+ years as the head writer/creative strategist for Uproxx Media. Suzanne is a content marketer, writer, and fact-checker. She holds a ...